-
Barber D L, Wherry E J, Masopust D. Restoring function in exhausted CD8 T cells during chronic viral infection[J]. Nature, 2006, 439(): 682-687. doi: 10.1038/nature04444
-
Bertoletti A, Ferrari C, Fiaccadori F. HLA class Ⅰ-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen[J]. Proc Natl Acad Sci USA, 1991, 88(): 10445-10449. doi: 10.1073/pnas.88.23.10445
-
Bertoletti A, Chisari F V, Penna A. Definition of a minimal optimal cytotoxic T-cell epitope within the hepatitis B virus nucleocapsid protein[J]. J Virol, 1993, 67(): 2376-2380.
-
Betts M R, Brenchley J M, Price D A. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation[J]. J Immunol Methods, 2003, 281(): 65-78. doi: 10.1016/S0022-1759(03)00265-5
-
Boni C, Fisicaro P, Valdatta C. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection[J]. J Virol, 2007, 81(): 4215-4225. doi: 10.1128/JVI.02844-06
-
Chisari F V, Ferrari C. Hepatitis B virus immunopathogenesis[J]. Annu Rev Immunol, 1995, 13(): 29-60. doi: 10.1146/annurev.iy.13.040195.000333
-
Colonno R J, Genovesi E V, Medina I. Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection[J]. J Infect Dis, 2001, 184(10): 1236-1245. doi: 10.1086/jid.2001.184.issue-10
-
Cote P J, Gerin J. In vitro activation of woodchuck lymphocytes mesured by radiopurine incorporation and interluekin-2 production: implications for modeling immunity and therapy in hepatitis B virus infection[J]. Hepatology, 1995, 22(): 687-699.
-
Couillin I, Pol S, Mancini M F. Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens[J]. J Infect Dis, 1999, 180(): 15-26. doi: 10.1086/jid.1999.180.issue-1
-
Day C L, Kaufmann D E, Kiepiela P. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression[J]. Nature, 2006, 443(): 350-354. doi: 10.1038/nature05115
-
Frank I, Budde C, Fiedler M. Acute resolving woodchuck hepatitis virus (WHV) infection is associated with a strong cytotoxic T-lymphocyte response to a single WHV core peptide[J]. J Virol, 2007, 81(): 7156-7163. doi: 10.1128/JVI.02711-06
-
Freeman G J, Wherry E J, Ahmed R. Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade[J]. J Exp Med, 2006, 203(): 2223-2227. doi: 10.1084/jem.20061800
-
Guidotti L G, Rochford R, Chung J. Viral clearance without destruction of infected cells during acute HBV infection[J]. Science, 1999, 284(): 825-829. doi: 10.1126/science.284.5415.825
-
Hervas-Stubbs S, Lasarte J J, Sarobe P. Therapeutic vaccination of woodchucks against chronic woodchuck hepatitis virus infection[J]. J Hepatol, 1997, 27(): 726-737. doi: 10.1016/S0168-8278(97)80090-6
-
Hervas-Stubbs S, Lasarte J J, Sarobe P. T-helper cell response to woodchuck hepatitis virus antigens after therapeutic vaccination of chronicallyinfected animals treated with lamivudine[J]. J Hepatol, 2001, 35(): 105-111. doi: 10.1016/S0168-8278(01)00063-0
-
Horiike N, Fazle Akbar S M, Michitaka K. In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B[J]. J Clin Virol, 2003, 32(): 156-161.
-
Hoofnagle J, Peters M, Mullen K D. Randomized controlled trial of recombinant human alphainterferon in patients with chronic hepatitis B[J]. Gastroenterology, 1988, 95(): 1318-1325. doi: 10.1016/0016-5085(88)90367-8
-
Janssen H L, van Zonneveld M, Senturk H. Rotterdam Foundation for Liver Research. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial[J]. Lancet, 2005, 365(): 123-129.
-
Jung M C, Gruner N, Zachoval R. Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies : induction of a vaccine-specific CD4+ T-cell proliferation response in chronic hepatitis B carriers[J]. Vaccine, 2002, 20(): 3598-3612. doi: 10.1016/S0264-410X(02)00309-2
-
Kreuzfelder E, Menne S, Ferencik S. Assessment of peripheral blood mononuclear cell proferation by 2[J]. Clin Immunol Immunpathol, 1996, 78(): 223-227. doi: 10.1006/clin.1996.0033
-
Lau G K, Piratvisuth T, Luo K X. Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B[J]. N Engl J Med, 2005, 352(): 2682-2695.
-
Locarnini S, Mason W S. Cellular and virological mechanisms of HBV drug resistance[J]. J Hepatol, 2006, 44(): 422-431. doi: 10.1016/j.jhep.2005.11.036
-
Lu M, He L F, Xu Y, et al. 2008. Evaluation of combination therapies of chronic HBV infection with lamivudine and DNA-vaccines or antigen-antibody complexes in the woodchuck model. J Virol, in press.
-
Lu M, Roggendorf M. Evaluation of New Approaches to Prophylactic and Therapeutic Vaccinations against Hepatitis B Viruses in the Woodchuck Model[J]. Intervirology, 2001, 44(): 124-131. doi: 10.1159/000050039
-
Lu M, Klaes R, Menne S. Induction of antibodies to the PreS region of surface antigens of woodchuck hepatitis virus (WHV) in chronic carrier woodchucks by immunizations with WHV surface antigens[J]. J Hepatol, 2003, 39(): 405-413. doi: 10.1016/S0168-8278(03)00241-1
-
Lu M, Menne S, Yang D. Immunomodulation as an option for the treatment of chronic hepatitis B virus infection: preclinical studies in the woodchuck model[J]. Expert Opin Investig Drugs, 2007, 16(): 787-801. doi: 10.1517/13543784.16.6.787
-
Maini M K, Boni C, Lee C K. The role of virus-specific CD8 (+) cells in liver damage and viral control during persistent hepatitis B virus infection[J]. J Exp Med, 2000, 191(): 1269-1280. doi: 10.1084/jem.191.8.1269
-
Maini M K, Boni C, Ogg G S. Direct ex vivo analysis of hepatitis B virusspecific CD8+ T cells associated with the control of infection[J]. Gastroenterology, 1999, 117(): 1386-1396. doi: 10.1016/S0016-5085(99)70289-1
-
Maschke J, Menne S, Jacob J R. Thymidine utilization abnormality in proliferating lymphocytes and hepatocytes of the woodchuck[J]. Vet Immunol Immunopath, 2001, 6403(): 1-18.
-
Menne S, Roneker C A, Korba B E. Immunization with surface antigen vaccine alone and after treatment with 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl)-uracil (L-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis virus infection[J]. J Virol, 2002, 76(): 5305-5314. doi: 10.1128/JVI.76.11.5305-5314.2002
-
Menne S, Maschke J, Tolle T K. Characterization of T-cell response to woodchuck hepatitis virus core protein and protection of woodchucks from infection by immunization with peptides containing a T-cell epitope[J]. J Virol, 1997, 71(): 65-74.
-
Missale G, Redeker A, Person J. HLA-A31-and HLA-Aw68-restricted cytotoxic T cell responses to a single hepatitis B virus nucleocapsid epitope during acute viral hepatitis[J]. J Exp Med, 1993, 177(): 751-762. doi: 10.1084/jem.177.3.751
-
Nayersina R, Fowler P, Guilhot S. HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection[J]. J Immunol, 1993, 150(): 4659-4671.
-
Pol S, Nalpas B, Driss F. Efficacy and limitations of a specific immunotherapy in chronic hepatitis B[J]. J Hepatol, 2001, 34(): 917-921. doi: 10.1016/S0168-8278(01)00028-9
-
Pol S, Driss F, Michel M L. Specific vaccine therapy in chronic hepatitis B infection[J]. Lancet, 1994, 344(): 342-.
-
Ponzetto A, Cote P J, Ford E C. Core antigen and antibody in woodchucks after infection with woodchuck hepatitis virus[J]. J Virol, 1984, 52(): 70-76.
-
Raney A K, Hamatake R K, Hong Z. Agents in clinical development for the treatment of chronic hepatitis B[J]. Expert Opin Investig Drugs, 2003, 12(): 1281-1295. doi: 10.1517/13543784.12.8.1281
-
Rehermann B, Fowler P, Sidney J. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis[J]. J Exp Med, 1995, 181(): 1047-1058. doi: 10.1084/jem.181.3.1047
-
Roggendorf M, Lu M. 2005. Woodchuck hepatitis virus. In: Viral Hepatitis (Thomas T H, Zuckermann A, Lemon S. ed. ), 3rd edition, Oxford: Blackwell Publishing Ltd. p210-224
-
Roggendorf M, Lu M. 2006. Therapeutic vaccination in chronic hepadnavirus infection. In: New concepts of antiviral therapy (Dogner E, Holzenburg A. ed. ), Part 1. New York: Springer Berlin Heidelberg. p3-20
-
Rubio V, Stuge T B, Singh N. Ex vivo identification, isolation and analysis of tumorcytolytic T cells[J]. Nat Med, 2003, 9(): 1377-1382. doi: 10.1038/nm942
-
Summers J, Smolec J M, Snyder R. A virus similar to human hepatitis B virus associated with hepatitis and hepatoma in woodchucks[J]. Proc Natl Acad Sci USA, 1978, 75(): 4533-4537. doi: 10.1073/pnas.75.9.4533
-
Tang T J, Kwekkeboom J, Mancham S. Intrahepatic CD8+ T-lymphocyte response is important for therapy-induced viral clearance in chronic hepatitis B infection[J]. J Hepatol, 2005, 43(): 45-52. doi: 10.1016/j.jhep.2005.01.038
-
Thimme R, Chang K M, Pemberton J. Degenerate immunogenicity of an HLA-A2-restricted hepatitis B virus nucleocapsid cytotoxic T-lymphocyte epitope that is also presented by HLAB51[J]. J Virol, 2001, 75(): 3984-3987. doi: 10.1128/JVI.75.8.3984-3987.2001
-
Thimme R, Wieland S, Steiger C. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection[J]. J Virol, 2003, 77(): 68-76. doi: 10.1128/JVI.77.1.68-76.2003
-
Thimme R, Wieland S, Steiger C. CD8+ T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection[J]. J Virol, 2003, 77(): 68-76. doi: 10.1128/JVI.77.1.68-76.2003
-
Webster G J, Reignat S, Maini M K. Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms[J]. Hepatology, 2000, 32(): 1117-1124. doi: 10.1053/jhep.2000.19324
-
Wen Y M, Wu X H, Hu D C. Hepatitis B vaccine and anti-HBs complex as approach for vaccine therapy[J]. Lancet, 1995, 345(): 1575-1576.
-
Wong D C, Shih J W K, Purcell R H. Natural and experimental infection of woodchucks with woodchuck hepatitis virus, a measured by new, specific assays for woodchuck surface antigen and antibody[J]. J Clin Microbiol, 1982, 15(): 484-490.
-
Xu D Z, Huang K L, Zhao K. Vaccination with recombinant HBsAg-HBIG complex in healthy adults[J]. Vaccine, 2005, 23(): 2658-2664. doi: 10.1016/j.vaccine.2004.10.040
-
Yalcin K, Acar M, Degertekin H. Specific hepatitis B vaccine therapy in inactive HBsAg carriers: a randomized controlled trial[J]. Infection, 2003, 31(): 221-225.
-
Yao X, Zheng B, Zhou J. Therapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients[J]. Vaccine, 2007, 25(): 1771-1779. doi: 10.1016/j.vaccine.2006.11.019
-
Zelinskyy G, Robertson S J, Schimmer S. CD8+ T-cell dysfunction due to cytolytic granule deficiency in persistent Friend retro virus infection[J]. J Virol, 2005, 79(): 10619-10626. doi: 10.1128/JVI.79.16.10619-10626.2005
-
Zhou J H, Ferencik S, Rebmann V. Molecular genetic and biochemical analysis of woodchuck (Marmota monax) MHC class Ⅰ polymorphism[J]. Tissue Antigens, 2003, 61(): 240-248. doi: 10.1034/j.1399-0039.2003.00036.x